Sanofi Pasteur expands with plans for new quality-control building; AstraZeneca loses appeal in Germany over Seroquel generics;

@FiercePharma:  JPM: $GSK ready to shift off Advair; $TEVA CEO lists buyout reqs; $PFE building PCSK9 "franchise." Article | Follow @FiercePharma

@CarlyHFierce:  Big Pharma vs. 'growth pharma'? Let Actavis chief detail the differences. More | Follow @CarlyHFierce

> Sanofi Pasteur unveiled plans for a new, 27,000-square-foot quality-control building. Story

> AstraZeneca ($AZN) lost an appeal in Germany's Federal Court to block generic drugmakers from selling cheap copycats of its anti-psychotic drug Seroquel XR. More

> Doctors should question screening a wider group of patients for hepatitis C, even in light of new drugs that can cure the disease, according to a new study published in the British Medical Journal. Story

> Pfizer ($PFE) issued a letter to U.K. doctors warning them that even though its patent on anti-epilepsy drug pregabalin has expired, the company's patent on the med's use for pain treatment is still in effect until 2017. Item

@EmilyWFierce: Good news, reps: Docs still prefer traditional marketing to digital when writing Rx. FiercePharmaMarketing story | Follow @EmilyWFierce

> Bard loses bid to delay vaginal mesh trial proceedings. Article

> DexCom: new CEO reports patient base grew by 50% in 2014. More

> Stakeholders look for clues to FDA's 2015 intentions regarding health IT. Story

Biotech News

@FierceBiotech: Intrexon and Ziopharm buy into CAR-T in $100M deal. Story | Follow @FierceBiotech

@JohnCFierce: First #FDA approved obesity device since 2007. More | Follow @JohnCFierce

> NeuroPhage wraps a $27M round to advance its Alzheimer's drug. Item

> Pfizer's cooking up a PCSK9-blocking pill. More

> Tobira eyes Wall Street with Regado merger, targeting NASH. More

Drug Delivery News

> Intersect ENT announces prelim Q4 financials at JPM, defining goals for its drug-loaded stents. More

> Tekmira stock soars on acquisition of OnCore to strengthen hep B pipeline. Story

> Pill-maker Capsugel collects Australian uni's tech for greater bioavailability. Article

> Extended-release drugs to face extra scrutiny from FDA's new Office of Pharmaceutical Quality. Item

> Alnylam and Isis strengthen RNAi alliance, agree to swap IP. More

Diagnostics News

> Roche snatches up majority share in Foundation Medicine for $1B plus milestones. News

> Biocept joins up with Insight Genetics for lung cancer test. Report

> Qiagen acquires Enzymatics, gains NGS partner ArcherDX. Story

> Biodesix ropes in $12M in Series E financing for blood-based lung cancer Dx. More

> Qiagen exceeds 2014 placement goals for molecular Dx, hedges its bets on continued success. Article

Pharma Marketing News

> Shire CEO sees 'home turf' marketing advantage with NPS buy. Report

> Actavis CEO: We may be big, but we don't want to be Big Pharma. News

> Some ad types are calling it: 'Pharmageddon' is over. DTC is back. Article

> Turning drug adherence into a game actually works, study finds. Report

> Good news, reps: Docs still prefer traditional marketing to digital when writing Rx. More

And Finally… Pharma execs are staying optimistic about business in 2015, according to a new survey, with more than half of individuals saying that conditions will be better for their companies in the coming year. More

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.